As the Coronavirus 2019 (COVID-19) epidemic continues to wreak havoc on human health, both old and new pharmaceutical companies are scrambling to develop safer and more effective vaccines against the virus. SARS – Cov-2).
The US Food and Drug Administration (FDA) was among those who received emergency use of the vaccine. Moderna is a pioneer in the field of RNA treatment and immunizations. He used this platform to enter areas such as infectious and cancer vaccines, as well as delivery technology and the treatment of chronic health conditions.
The company plans to expand its production capacity to 3 billion doses by 2022. It already has supply contracts with many high-income countries and has delivered millions of doses worldwide.
Model and Vaccine Schedule
The modernization and MRNA vaccine opens a stable form of SARS-CoV-2 in the pre-combination form. This leaflet was developed by Moder and Scientists in collaboration with the National Institute of Allergy and Infectious Diseases (NID) Vaccination Research Center.
The first group of vaccines was prepared on February 7, 2020 and analyzed before being sent to the NIH on February 24, which is less than 45 days from the time of selection to the Phase 1 test.
Linn May 12, 2021 On May 12, 2021, a secondary study looked at the pace of vaccination to the speed of vaccination. This includes adults over the age of 18 and divided into two age groups by the age of 55.
On September 29, the second interim data analysis of 56, 70-70 and 71+ year old participants was published. Linn At the end of November, Modrena was granted a USSFA permit for December 18, 2020, for 18 years or more for emergency use.
Conditional Trading Permit (CMA) application with European Medicines Agency also approved. It is currently licensed in the United Kingdom, Canada, Israel, the European Union, Singapore and Taiwan, along with other countries. It is being evaluated in many other countries and many can follow.
Linn The April 30, 2021 Modernization and MRI vaccine vaccine has been added to the World Health Organization (WHO) Emergency Use List (EL), a tool to protect against COVID-19 for people 18 or older.
Raise the vaccine from the types that will appear later
It is also developing immunosuppressive modulators for the antibodies that are already partially or completely resistant to the antibodies, and is also developing immunizations against COVID-19. These include MRI-1273.351 and the first mRNA-1273 versus mRNA-1273.351, which opposes South African variance B.1351 and mRNA-1273.211.
Pre-clinical test data is available on pre-form Bioraxive * Server, pending peer review for publication. Level 2 testing is currently underway.
The importance of EUL
EUL is an assessment designed to test the safety, effectiveness, and quality of new health products to expand their reach. The process uses two-stage clinical trial data from independent WHO investigators and independent assessments of the above criteria.
The current EUL follows all the scientific data provided by the company, especially the level 3 clinical research data. Analysis of this data Reported by the company on November 30, 2020 and will continue to provide the information to the World Health Organization. The manufacturer is responsible for the EUL deadline for providing the evaluation information.
The World Health Organization (WHO) Strategic Advisory Team (SIG) In January 2021, it is recommended that all 92% effective immunizations be given to all adults in the first two weeks of the first dose.
Moder and Vaccination Il, Astra-Zeneka-Sik Bayo, Indian Serum Institute and John & Johnson are the first and foremost recipients of the Pipeser Vaccines and are being evaluated by China Sinofarm and Sinovak.
The introduction of modules and vaccines to EUL will speed up the import and use of the vaccine as it will provide immediate control to any country involved in the vaccine. In addition, organizations such as UNICEF (United Nations Children’s Fund) can now purchase the vaccine and distribute it to needy countries.
In addition, the newly established COVAX facility requires a United Nations-backed program to coordinate the procurement and distribution of COVID-19 vaccines to many low- and middle-income countries.
* Important Notice
BioXivev produces the first unadulterated scientific reports, and therefore, should not be seen as a conclusion, as a clinical practice / health-related behavior, or as evidence.